# Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

> **NCT01088620** · PHASE2 · SUSPENDED · sponsor: **WiSP Wissenschaftlicher Service Pharma GmbH** · enrollment: 134 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01088620
- **Lead sponsor:** WiSP Wissenschaftlicher Service Pharma GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2010-04
- **Primary completion:** 2013-01
- **Final completion:** 2014-01
- **Target enrollment:** 134 (ESTIMATED)
- **Why stopped:** the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has not yet been verified
- **Last updated:** 2013-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01088620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01088620, "Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01088620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*